+ Watch MITI
on My Watchlist
MITI - Offer huge upside in the BioTech sector. I firmly believe this company will get bought out in the next 12-24 months.
I like the research MITI is doing
Market sentiment on selected stocks
From the board chair to the other principals, they are all selling shares like there is no tomorrow. Get out now while the gettin is good!
Phase 1 Data on MT110 2nd Bite for solid tumors late this year early next!
This company may be on the verge of a possible cure for cancer.
their patented safe antibody platform will change the standard in treatment of cancer. they are going to create a royality system of revenues sold throughout the pharma industry. in 10 years , heres another 10 bagger. Dr. D
4.5 and above is strong resistance in the near term.
- Forecasted Earnings per Share of $-0.73 per share- P/E of of -4.82- Earnings Yield of -20.74 percent- Growth to P/E Ratio of -0.20
bad company ready to go down
Listen carefully: This stock will be at $20 on or around December 6th-9th. These dates are the 50th ASH meeting where MITI will present phae II data from its drug MT203. If results are positive, the stock will soar. So far, results have been close to 100% positive. December will be the time of the catalyst. Get in before its too late. Good Luck
The worst company on earth.
Hope I'm not too late on this one....
I've been in MITI since Dec 07. Potential of BITE is amazing and although MT103 is their lead candidate, they have many BITE platforms in development. Check out the Science Magazine article that just rocketed the stock into the high 5's (as high as 6.50. Listen to the company CC that was predicated on the Science Magazine article. Check out the Science Advisory Board panel mambers that MITI stood up a a steering committee for their pending products.7 of 7 patients tested at the highest doses (which are 5 orders of magnitude lower than existing antibody therapies) showed complete or partial remission. Longest treated candidate is still in remission over a year later. Even though the stock has moved significantly this year, if the additional data which will be released in Dec at ASCO continues to show promise, the stock will continue to move up sharply.
cancer research should provide valuable results and may end some forms of cancer
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions